Last Update: Nov 15, 2024
An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment
ClinicalTrials.gov Identifier:
Novartis Reference Number:CAIN457A02001B
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The purpose of this study is to assess long term safety in participants who have
completed a Novartis trial with secukinumab, have been judged by the investigator to
benefit from continued treatment with secukinumab, and are unable to obtain the marketed
secukinumab formulation.

Autoimmunity, Inflammation
Phase4
Recruiting
715
Dec 22, 2020
Feb 29, 2028
All
6 Years - (Child, Adult, Older Adult)

Interventions

Biological

Secukinumab s.c. injection

Secukinumab pre-filled syringes (PFS) for s.c. injection

Eligibility Criteria

Inclusion Criteria:

1. Signed informed consent must be obtained for adult participants before any
assessment is performed. Written informed assent and parental permission (age as per
local law) must be obtained for pediatric participants before any assessment is
performed. If participants reach age of consent (age as per local law) during the
study, they will need to also sign the corresponding study informed consent(s).

2. Ability to communicate effectively with the investigator, to understand and willing
to comply with the requirements of the study.

3. Participant has completed treatment per protocol in a Novartis study of secukinumab
(unless otherwise specified in a parent study protocol). Participants, who derive
benefit from the treatment with secukinumab but have not completed the treatment in
certain parent studies, due to parent study termination by Novartis, may be eligible
if the termination was due to reasons other than safety or lack of efficacy
(technical / administrative reasons).

4. Participant is deriving benefit from secukinumab, investigator believes he/she would
continue to derive benefit from secukinumab and the benefit outweighs the risk,
based on the investigator's judgement.

5. Participant is unable to obtain access to the marketed secukinumab formulation per
local prescription and/or reimbursement guidelines.

Exclusion Criteria:

1. Participant has prematurely discontinued study treatment in the parent protocol.

2. Women of childbearing potential, defined as all women physiologically capable of
becoming pregnant, unless they are using methods of contraception during the entire
study or longer if required by locally approved prescribing information (e.g., in
European Union (EU) 20 weeks).

Novartis Investigative Site

Recruiting

Salvador,BA,40150 150,Brazil

Novartis Investigative Site

Recruiting

Vitoria,ES,29055 450,Brazil

Novartis Investigative Site

Recruiting

Juiz de Fora,MG,36010 570,Brazil

Novartis Investigative Site

Recruiting

Sao Paulo,SP,01244-030,Brazil

Novartis Investigative Site

Recruiting

Sao Paulo,SP,04266 010,Brazil

Novartis Investigative Site

Recruiting

Rio de Janeiro,20241-180,Brazil

Novartis Investigative Site

Recruiting

Sao Jose do Rio Preto,15090 000,Brazil

Novartis Investigative Site

Recruiting

Plovdiv,4002,Bulgaria

Novartis Investigative Site

Recruiting

Sofia,1431,Bulgaria

Novartis Investigative Site

Recruiting

Sofia,1784,Bulgaria

Novartis Investigative Site

Recruiting

Urumqi,Xinjiang,830001,China

Novartis Investigative Site

Recruiting

Chongqing,Chongqing,400010,China

Novartis Investigative Site

Recruiting

Yangzhou,Jiangsu,225001,China

Novartis Investigative Site

Recruiting

Shanghai,200040,China

Novartis Investigative Site

Recruiting

Wuhan,Hubei,430030,China

Novartis Investigative Site

Recruiting

KunMing,Yun Nan,650000,China

Novartis Investigative Site

Recruiting

Xiamen,Fujian,361001,China

Novartis Investigative Site

Recruiting

Nanchang,Jiangxi,330006,China

Novartis Investigative Site

Recruiting

Shanghai,200050,China

Novartis Investigative Site

Recruiting

Changsha,Hunan,410011,China

Novartis Investigative Site

Recruiting

Wenzhou,Zhejiang,325000,China

Novartis Investigative Site

Recruiting

Guang Zhou,Guangdong,510120,China

Novartis Investigative Site

Recruiting

Pingxiang,Jiangxi,337000,China

Novartis Investigative Site

Recruiting

Shanghai,200127,China

Novartis Investigative Site

Recruiting

Baotou,Inner Mongolia,014010,China

Novartis Investigative Site

Recruiting

Beijing,100000,China

Novartis Investigative Site

Recruiting

Guangzhou,Guangdong,510080,China

Novartis Investigative Site

Recruiting

Chang Chun,Jilin,130021,China

Novartis Investigative Site

Recruiting

Hefei,Anhui,230001,China

Novartis Investigative Site

Recruiting

Tianjin,300052,China

Novartis Investigative Site

Recruiting

Hohhot,Inner Mongolia,10050,China

Novartis Investigative Site

Recruiting

Bengbu,233004,China

Novartis Investigative Site

Recruiting

Guangzhou,Guangdong,510515,China

Novartis Investigative Site

Recruiting

Linyi,Shandong,276000,China

Novartis Investigative Site

Recruiting

Zhejiang,315016,China

Novartis Investigative Site

Recruiting

Hefei,Anhui,230601,China

Novartis Investigative Site

Recruiting

Nanjing,Jiangsu,210008,China

Novartis Investigative Site

Recruiting

Shantou,Guangdong,515041,China

Novartis Investigative Site

Recruiting

Chengdu,Sichuan,610041,China

Novartis Investigative Site

Recruiting

Beijing,Beijing,100044,China

Novartis Investigative Site

Recruiting

Nanjing,Jiangsu,210009,China

Novartis Investigative Site

Recruiting

Jinan,250012,China

Novartis Investigative Site

Recruiting

Shenzhen,Guangdong,518020,China

Novartis Investigative Site

Recruiting

Ibague,Tolima,730006,Colombia

Novartis Investigative Site

Recruiting

Bogota,110221,Colombia

Novartis Investigative Site

Recruiting

Cundinamarca,111121,Colombia

Novartis Investigative Site

Recruiting

Bucaramanga,Santander,0001,Colombia

Novartis Investigative Site

Recruiting

Praha 11,14900,Czechia

Novartis Investigative Site

Recruiting

Praha 2,128 50,Czechia

Novartis Investigative Site

Recruiting

Praha 4,140 59,Czechia

Novartis Investigative Site

Recruiting

Ostrava,Czech Republic,772 00,Czechia

Novartis Investigative Site

Recruiting

Praha 5,150 06,Czechia

Novartis Investigative Site

Recruiting

Brno-Zidonice,CZE,61500,Czechia

Novartis Investigative Site

Recruiting

Uherske Hradiste,686 01,Czechia

Novartis Investigative Site

Recruiting

Hradec Kralove,CZE,500 05,Czechia

Novartis Investigative Site

Recruiting

Brno Bohunice,625 00,Czechia

Novartis Investigative Site

Recruiting

Guatemala,01009,Guatemala

Novartis Investigative Site

Recruiting

Guatemala City,01010,Guatemala

Novartis Investigative Site

Recruiting

Guatemala,01001,Guatemala

Novartis Investigative Site

Recruiting

Nashik,Maharashtra,422101,India

Novartis Investigative Site

Recruiting

Bialystok,15-351,Poland

Novartis Investigative Site

Recruiting

Sochaczew,96-500,Poland

Novartis Investigative Site

Recruiting

Torun,87-100,Poland

Novartis Investigative Site

Recruiting

Warszawa,02 637,Poland

Novartis Investigative Site

Recruiting

Yaroslavl,150003,Russian Federation

Novartis Investigative Site

Recruiting

Moscow,119296,Russian Federation

Novartis Investigative Site

Recruiting

Saint Petersburg,197198,Russian Federation

Novartis Investigative Site

Recruiting

Kazan,420064,Russian Federation

Novartis Investigative Site

Recruiting

Panorama,Western Cape,7500,South Africa

Novartis Investigative Site

Recruiting

Stellenbosch,7600,South Africa

Novartis Investigative Site

Recruiting

Santiago De Compostela,Galicia,15706,Spain

Novartis Investigative Site

Recruiting

Madrid,28046,Spain

Novartis Investigative Site

Recruiting

Valencia,46026,Spain

Novartis Investigative Site

Recruiting

Bern,3010,Switzerland

Novartis Investigative Site

Recruiting

St Gallen,9007,Switzerland

Novartis Investigative Site

Recruiting

Basel,4031,Switzerland

Purushotham Akther and Roshan Kotha MD Inc

Recruiting

La Mesa,California,91942,United States

Roshan Kotha
Eva Duran

Denver Arthritis Clinic

Recruiting

Denver,Colorado,80230,United States

Christopher Ryan Antolini

West Tennessee Research Institute

Recruiting

Jackson,Tennessee,38305,United States

Jacob A. Aelion
Kim Smith

Illinois Bone And Joint Institute

Recruiting

Hinsdale,Illinois,60521,United States

Angela R Crowley
Swarnika Sampat

Accurate Clinical Research Inc

Recruiting

San Antonio,Texas,78229,United States

Philip Waller
Viet Ta

Precn Comprehensive Clnl Rsch Solns

Recruiting

San Leandro,California,94578,United States

Suneet Grewal

FL Medical Clinic Orlando Health

Recruiting

Zephyrhills,Florida,33542,United States

Endora Ankrah
Natalie Faith

Southwest Rheum Rsrch LLC

Recruiting

Mesquite,Texas,75150,United States

Atul K Singhal
Nancy De La Cruz

Medvin Clinical Research

Recruiting

Van Nuys,California,91405,United States

Samy Metyas

Ahmed Arif Medical Research Center

Recruiting

Grand Blanc,Michigan,48439,United States

Ali Karrar

Dawes Fretzin Clinical Rea Group

Recruiting

Indianapolis,Indiana,46256,United States

Joan Prusa
Scott Fretzin

Homestead Assoc In Research Inc

Recruiting

Homestead,Florida,33033,United States

Gilberto Seco
Jhenny Grullon

Center for Rheumatology Research

Recruiting

West Hills,California,91307,United States

Lauren Jackson
Nazanin Firooz

Rheumatology Pulmonary Clinic

Recruiting

Beckley,West Virginia,25801,United States

Catie Webb
Wassim S Saikali

Oregon Health Sciences University

Recruiting

Portland,Oregon,97239,United States

Atul Deodhar
Yuki Harry

Integral Rheumatology and Immunology Specialists IRIS

Recruiting

Plantation,Florida,33324,United States

Guillermo Valenzuela

Altoona Center for Clin Res

Recruiting

Duncansville,Pennsylvania,16635,United States

Alan J Kivitz
Mary Beyer

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Novartis Pharmaceuticals